The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor1α promoter
Abstract
For effective gene therapy of chronic disease, persistent transgene expression at therapeutic levels is required. Clinical studies of airway gene transfer in patients with cystic fibrosis (CF) have resulted in short-lived transgene expression. We used intra-nasal dosing of naked plasmid DNA to the murine lung as a model for investigating the duration of airway gene transfer from a series of reporter expression plasmids. Transgene expression was transient when mediated by the viral promoters CMV, RSV and SV40, falling to less than 10% of peak expression after 2 weeks, although the presence of the adenoviral E4ORF3 gene in cis, resulted in extended duration of reporter activity from the CMV promoter. Transient expression from these promoters was not due to loss of the vector as determined by quantitative TaqMan PCR analysis. However, use of the promoters from the human polybiquitin C (UbC) and the elongation factor 1alpha (EF1alpha) genes resulted in persistent gene expression in the mouse lung. The UbC promoter directed high-level reporter activity which was maintained for up to 8 weeks and was still detectable 6 months after a single administration. Such persistent airway transgene expression from a nonviral vector without the concomitant expression of a potential antigen has not been reported previously. Thus, despite the persistence of vector DNA in vivo, attenuation of promoter function may lead to silencing of transgene expression and careful selection of promoter sequenc…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“thus providing the relevant advantage of minimizing the potential risk of on-target chromosomal translocations61.”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [61]
Citations
Cites
Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741
A novel cationic liposome reagent for efficient transfection of mammalian cells
Gao, X., & Huang, L. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91366-k · Cited by 847
Lee, E. R., Marshall, J., Siegel, C., Jiang, C., Yew, N. S., Nichols, M., Nietupski, J. B., Ziegler, R. J., Lane, M. B., Wang, K. X., et al. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.14-1701 · Cited by 443
DNA Methylation and Silencing of Gene Expression
Newell-Price, J. D. C., Clark, A. J. L., & King, P. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00248-4 · Cited by 330
Qin, L., Ding, Y., Pahud, D. R., Chang, E., Imperiale, M. J., & Bromberg, J. S. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.17-2019 · Cited by 315
Role of covalent modifications of histones in regulating gene expression
Spencer, V. A., & Davie, J. (1999) · Gene · doi:10.1016/s0378-1119(99)00405-9 · Cited by 306
Löser, P., Jennings, G. S., Strauss, M., & Sandig, V. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.180-190.1998 · Cited by 277
Uetsuki, T., Naito, A., Nagata, S., & Kaziro, Y. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83619-5 · Cited by 272
Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies.
Carvalho, T., Seeler, J.-S., Öhman, K., Jordan, P., Pettersson, U., Akusjärvi, G., Carmo‐Fonseca, M., & Dejean, A. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.131.1.45 · Cited by 267
Cited by
Sorted by citations
Items 201–212 of 212
Engineering generic vaccine vectors
Sudhakar, P., Kiranmayi, M. J., Sankarpandian, S., Rao, M. S., Vijayalakshmi, M., & Rao, K. R. S. S. (2011) · International Journal of Biomedical Engineering and Technology · doi:10.1504/ijbet.2011.040455
Intranasal delivery of pGDNF nanoparticles for Parkinson's disease
Harmon, B. T. (2013) · doi:10.17760/d20003327
Zhou, Y., & Huang, Q. (2011) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2011.00879
Park, S.-Y., Kim, S., Lee, W., Lee, H., Kim, H., Chung, J.-K., & Kim, S. E. (2008)
Gene therapy for methylmalonic aciduria.
Wong, E. S. Y. (2012) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Gene Therapy in Nonneoplastic Lung Disease
Allen, T. C., & Cagle, P. T. (2008) · Molecular pathology library · doi:10.1007/978-0-387-72430-0_48
Chauhan, M., Daugherty, A. L., Khadir, F., Duzenli, O. F., Hoffman, A., Wan, O., Tinklenberg, J. A., Kang, P. B., Aslanidi, G., & Pacak, C. A. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201681
Transthoracic Electroporation for the Treatment of Acute Respiratory Distress Syndrome
Young, J. L., Lester, G. M. S., Zhou, R., & Dean, D. A. (2025) · Springer eBooks · doi:10.1007/978-3-319-26779-1_254-1
Mazinani, M., Kozani, P. S., & Rahbarizadeh, F. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05623-w
Lester, G. M. S., Huang, J., Barravecchia, M., Whigham, L. N., Hooker, J. M., Bentley, K. L. D. M., Young, J. L., Zhou, Z., & Dean, D. A. (2026) · Gene Therapy · doi:10.1038/s41434-026-00634-0
Metadata
- Authors
- Gill, D., Smyth, S., Goddard, C., Pringle, I., Higgins, C., Colledge, W., & Hyde, S.
- Affiliations
- John Radcliffe Hospital (GB)
- University of Cambridge (GB)
- Hammersmith Hospital (GB)
- Venue
- Gene Therapy
- Published
- 2001-10-01
- Volume
- 8
- Issue
- 20
- Pages
- 1539-1546
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2122003649
- Cited by
- 214
- References
- 34
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 4 · 2015: 6 · 2014: 9 · 2013: 7 · 2012: 12
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Cystic Fibrosis Trust
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Keywords
- persistent transgene expression, pulmonary gene therapy, promoter selection, cystic fibrosis, promoter silencing, reporter gene expression
- MeSH terms
- Administration, Inhalation, Animals, Avian Sarcoma Viruses, Cell Line, Cystic Fibrosis, Cytomegalovirus, Female, Gene Expression Regulation, Genetic Vectors, Humans, Luciferases, Lung, Mice, Inbred BALB C, Plasmids, Promoter Regions, Genetic, Simian virus 40, Time Factors, Genetic Therapy, Statistics, Nonparametric, Transgenes, Peptide Elongation Factor 1, Models, Animal, Ubiquitin C, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
